Skip to main content

Table 1 Association of impaired fasting glucose, diabetes and their management with other cardiovascular risk factors, medication prescription and presentation in 1637 patients with peripheral artery disease

From: Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study

  Diabetes category   
  1 2 3 4 5 Total P value
Number 655 (40.0%) 460 (28.1%) 150 (9.2%) 296 (18.1%) 76 (4.6%) 1637  
Age (years) 70.83 71.27 71.12 70.35 65.47 70.68 0.001
(63.28-76.98) (64.64-76.69) (66.19-76.91) (64.22-75.01) (59.74-72.07) (64.13-76.43)
Male 477 352 114 226 55 1224 0.591
(72.8%) (76.5%) (76.0%) (76.4%) (72.4%) (74.8%)
Hypertension 470 361 105 258 65 1259 <0.001
(71.8%) (78.5%) (70.0%) (87.2%) (85.5%) (76.9%)
Ever smoker 527 399 123 238 62 1349 0.074
(80.5%) (86.7%) (82.0%) (80.4%) (81.6%) (82.4%)
CHD 282 216 79 155 47 779 0.003
(43.1%) (47.0%) (52.7%) (52.4%) (61.8%) (47.6%)
eGFR (mL/min/1.73 m2) 76.39 73.37 74.22 74.93 69.17 74.93 0.040
(59.40-90.43)* (56.27-87.71) (51.99-87.76) (56.88-88.96)§ (44.47-91.02)|| (56.97-89.35)
Presenting complaint
Asymptomatic carotid stenosis 56 35 11 30 7 139 0.772
(8.5%) (7.6%) (7.3%) (10.1%) (9.2%) (8.5%)
Mild limb peripheral artery disease 151 91 25 89 25 381 0.001
(23.1%) (19.8%) (16.7%) (30.1%) (32.9%) (23.3%)
Aortic and peripheral artery aneurysm 302 225 84 88 8 707 <0.001
(46.1%) (48.9%) (56.0%) (29.7%) (10.5%) (43.2%)
Symptomatic carotid artery stenosis 90 70 15 43 8 226 0.491
(13.7%) (15.2%) (10.0%) (14.5%) (10.5%) (13.8%)
Critical limb ischaemia 56 39 15 46 28 184 <0.001
(8.5%) (8.5%) (10.0%) (15.5%) (36.8%) (11.2%)
Prescribed medication
Statin 392 325 92 232 61 1102 <0.001
(59.8%) (70.7%) (61.3%) (78.4%) (80.3%) (67.3%)
Aspirin 415 311 98 226 48 1098 0.003
(63.4%) (67.6%) (65.3%) (76.4%) (63.2%) (67.1%)
Other anti-platelets 130 90 37 72 21 350 0.194
(19.8%) (19.6%) (24.7%) (24.3%) (27.6%) (21.4%)
Beta-blockers 199 186 53 108 28 574 0.014
(30.4%) (40.4%) (35.3%) (36.5%) (36.8%) (35.1%)
Calcium channel blocker 155 142 50 99 27 473 0.004
(23.7%) (30.9%) (33.3%) (33.4%) (35.5%) (28.9%)
ACE inhibitor 227 182 58 153 52 672 <0.001
(34.7%) (39.6%) (38.7%) (51.7%) (68.4%) (41.1%)
ARB 142 94 34 94 17 381 0.005
(21.7%) (20.4%) (22.7%) (31.8%) (22.4%) (23.3%)
Metformin 0 0 0 245 40 285 <0.001
(82.8%) (52.6%) (17.4%)
Other oral hypoglycaemic 0 0 0 170 26 196 <0.001
(57.4%) (34.2%) (12.0%)
Insulin 0 0 0 0 76 76 <0.001
(100%) (4.6%)
Frusemide 54 43 14 39 23 173 <0.001
(8.2%) (9.3%) (9.3%) (13.2%) (30.3%) (10.6%)
  1. Serum creatinine was unavailable on 7*, 3 †, 3 ‡, 1 § and 1|| patients therefore eGFR could not be calculated. CHD = coronary heart disease; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate. Continuous variables are presented as median and inter-quartile range and assessed using the Kruskal Wallis test. Nominal variables are presented as number and percent and analysed using the Chi-squared test.
  2. Key to patient groups:
  3. 1: No diabetes; 2: Impaired fasting glucose; 3: Non-medicated diabetes; 4: Diabetes prescribed oral hypoglycaemics only; 5: Diabetes prescribed insulin.